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Abstract

In May 2005, the Food and Drug Administration (FDA) issued draft guidance
on the type of information to be posted on its new “Drug Watch” website—a site
intended to identify drugs for which it is actively evaluating early safety signals.
At this time, the FDA plans only to post information on drug products regulated by
the Center for Drug Evaluation and Research, therefore vaccines, blood products
and medical devices shall be excluded.
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FDA Issues Guidance Describing New
Drug Safety Website for Emerging Risks
In May 2005, the Food and Drug Administration
(FDA) issued draft guidance on the type of
information to be posted on its new “Drug
Watch” website—a site intended to identify drugs
for which it is actively evaluating early safety
signals. At this time, the FDA plans only to post
information on drug products regulated by the
Center for Drug Evaluation and Research,
therefore vaccines, blood products and medical
devices shall be excluded.
In its guidance, the FDA identified several
factors that it plans to consider when
determining what products and information
to post on this site, including whether:
•

New and emerging safety information
could significantly affect prescribing
decisions or how patients should be
monitored (e.g., a new possible drug-drug
interaction has been identified and needs
to be considered in prescribing)

•

Measures may be taken by providing
information that could help to prevent or
mitigate harm (e.g., limit prescribing to patients
most likely to benefit from the drug, be alert
for signs of serious adverse reactions)
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•

An unapproved (off-label) use of the drug
appears to pose a significant risk to patients

The FDA indicated that it intends to remove
products from the website as safety issues
are resolved. The guidance also warned
manufacturers about the consequences of
emphasizing a competitor’s listing on the Drug
Watch site or minimizing the effect of its own
listing, indicating that neither the fact that a
drug appears on Drug Watch nor the specific
information posted about it will generally

constitute substantial evidence or clinical
experience to support a comparative safety or
effectiveness claim. Accordingly, comparative
claims made in prescription drug promotion
based on information posted on the site may be
considered false or misleading marketing, as may
a company’s representations made to minimize
the effect of its own emerging risk information.
FDA Guidance

EUROPE
Abridged Marketing Authorization
Applies to Line Extension Product
with Different Dosage Schedule
In the most recent of four actions testing
the boundaries of the abridged marketing
authorization provisions relating to medicinal
products for human use, the UK High Court has
held—despite the fact that the European Court
of Justice (ECJ) has not specifically previously
considered the issue—where the data relied
upon relates to an authorized product (itself a
line extension of an earlier authorized product
with a different dosage schedule) the principles
set out in the three previous cases apply. As a
result, the three generic applicants in the case
were entitled to rely on such data, without
addition, and a further reference on interpretation to the ECJ was held to be unnecessary.
Merck Sharp and Dohme had challenged the
entitlement of the applicants to rely upon
data relating to two authorized osteoporosis
products in order to seek abridged marketing
authorization for their own products. EC
legislation states that abridged marketing
authorization may be sought where the applicant
can show that its product is “essentially similar”
to one that has been authorized for 10 years
(UK). The ECJ has held that data relating to
products authorized for less than this period,
but differing only in therapeutic indication,
bioavailability or pharmaceutical form to one
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so authorized, may be relied upon, provided the
test of “essential similarity” (same qualitative and
quantitative composition, same pharmaceutical
form, bioequivalent and no significant difference
in safety or efficacy) remains satisfied.
Merck v. Approved Prescription Services

Automatic Validity of Swiss Marketing
Authorizations in Liechtenstein
Impacts Duration of Supplementary
Protection Certificates

“UK Court of Appeal
further develops
principles of patent
claim construction.”

The ECJ has recently clarified that the automatic
validity of Swiss marketing authorizations in
the European Economic Area (EEA) member
state of Liechtenstein—result of a mutual
recognition agreement between these two
countries—means that such authorizations do
constitute the “first marketing authorization
in the community” for the purpose of granting
Supplementary Protection Certificates (SPC).
On joined references from the UK Patent Office
and the Luxembourg Administrative Court, Swiss
marketing authorizations were obtained several
months before authorizations in an EEA member
state other than Liechtenstein. The patentees
argued that the SPC sought should run from
the date of the later authorizations. The ECJ
disagreed on the basis that this would mean that
the patent and SPC holders should be able to take
advantage of more than the permitted 15 years’
exclusivity from the date of first authorization.
SPC may be granted for any active ingredient(s),
protected by patent and present in medicinal
products that have received EEA marketing
authorization. SPC confer the same rights as
the patent and take effect at the end of its term
for a period equal to that elapsing between
the date the patent application was lodged and
the date of the first EEA authorization. SPC
compensate for the delay in commercialization
caused by the authorization procedure. The
maximum duration of an SPC is five years.
This decision may have significant impact for
relevant patent holders. Many such patentees seek
early authorization in Switzerland prior to placing
their respective products on the EEA market some
months later. By calculating extended protection
from the date of this earlier authorization, these
patentees may now face significant profit losses.
In the case referred by the Luxembourg Court,
the patentee lost protection for a period greater
than two years. Patentees will now have to take
care that their Swiss marketing approvals do
not proceed faster than their EEA approvals.
Novartis v. Licensing Authorities

INTELLECTUAL PROPERTY
UNITED STATES

En Banc Review Denied
The Spring 2005 issue of PharmaBulletin reported
that the Federal Trade Commission (FTC) had filed
a brief in support of the generic drug manufacturer
to have the US Court of Appeals for the Federal
Circuit review a panel decision en banc as to
whether Teva—an ANDA applicant who had filed
a paragraph IV certification—had a reasonable
apprehension of suit to create jurisdiction for its
declaratory judgment action. On April 4, 2004, this
petition was denied (Teva Pharmaceuticals v. Pfizer).
This closely watched and controversial
decision is important for both pharmaceutical
and generic companies to consider in their
strategic decisions on patent enforcement
and generic competitor product launch.
Teva had filed an ANDA application, with a
paragraph IV certification, seeking approval from
the FDA to market its generic version of Pfizer’s
Zoloft® (sertraline hydrochloride), before Pfizer’s
patent expired. Under the provisions of the
Hatch-Waxman Act, Pfizer had 45 days to sue
Teva for patent infringement. When Pfizer did not
sue, Teva brought a declaratory judgment action
against Pfizer, seeking a determination that its
generic product did not infringe Pfizer’s patent.
The court held that merely listing a patent
in the Orange Book does not illustrate a
“reasonable apprehension” of being sued,
because listing is a statutory requirement,
“more is required for an actual controversy than
the existence of an adversely held patent��
.�”
Judges Garja and Dyk wrote dissenting opinions
on the denial. Judge Garja asserted that the panel
decision allowed “the statutory procedures to
be manipulated by the patent holders to the
clear and foreseeable detriment of the generic
drug industry.” Judge Dyk wanted the en banc
rehearing granted in order to answer the question
as to “whether a patent holder can delay [FDA]
approval of an application for a competing generic
drug by the simple expedient of refusing to
sue for infringement.” These opinions portend
further amendments to the Hatch-Waxman
Act. In the meantime, patentees may consider
not suing generic companies who have filed an
ANDA with a paragraph IV certification, as an
alternative strategy to Hatch-Waxman litigation.
Teva Pharmaceuticals USA Inc. v. Pfizer Inc.
2003 Medicarehttp://law.bepress.com/wilmer/art11
Act
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UK Court of Appeal Further Develops
Principles of Patent Claim Construction

India Adopts WTO Patent Law

Hot on the heels of the House of Lords
decision in Kirin-Amgen, the Court of Appeal has
taken the opportunity to further develop the
principles of the construction of patent claims.
The claimants, Mayne Pharma Pty Ltd and
Mayne Pharma Plc, initiated proceedings seeking
a declaration of non-infringement relating
to four patents owned by the defendant,
Pharmacia Italia SpA. Pharmacia Italia counterclaimed for infringement of one of these
patents, relating to an injectable ready-to-use
anticancer solution not “reconstituted from
a lyophilizate.” The sole issue at trial was the
interpretation of claim one of that patent.
Finding for Pharmacia Italia, the Court of Appeal
held, contrary to the trial court, that the patent
was infringed by Mayne Pharma’s product,
which had been subjected to a lyophilization
process. Its reason was that a pharmaceutical
manufacturer (the correct notional person
skilled in the art) would see that the essence
of the invention was the manufacture of a
ready-to-use solution that did not involve the
previously essential lyophilization stage.
In a short 10-page judgment, the court
noted with approval that the case had been
subjected to the streamlined procedure, going
“from start to determination on appeal in
less than 9 months” and offered the following
practical guidance as to claim construction:
•

The extent of protection (the monopoly)
is determined by the terms of the claims.

•

These are to be interpreted purposively—the
inventor’s purpose being ascertained
from the description and drawings.

•

Purpose is not however “the be-all and end-all”;
at “the end of the day” one is “concerned
with the meaning of the language used��
.�”
If, for example, a patentee has included an
obvious “deliberate limitation” in a claim,
this limitation has a meaning and cannot
be disregarded. Equally, where a word or
phrase with a particular contextual meaning
is used, this word or phrase may not
necessarily have that meaning in context.

•

There is no general “doctrine of equivalents��
.�”

Mayne Pharma v. Pharmacia Italia

Under legislation passed in late March, India
will begin granting patent protection for
pharmaceutical products, effectively prohibiting
the domestic manufacture of low-cost generics.
This is an important milestone for India, marking
its compliance with its obligations under the
WTO TRIPS (World Trade Organization Trade
Related Intellectual Property Rights) regime.
The new law provides that Indian companies
producing generics prior to January 1, 2005,
will be permitted to continue to do so, but
only if they apply for a manufacturing license
and pay a reasonable royalty to the patentee.
Product patents granted under the new regime
will remain in force for 20 years, during which
time the patentee will have exclusive rights
over the manufacture and sale of the drug.
Branded pharmaceutical companies
should welcome the passage of this bill.
Foreign filing strategies will have to be
reviewed to capture the new protections
afforded by this change in patent law.

“India will begin
granting patent
protection for
pharmaceutical
products.”

ANTITRUST/COMPETITION
UNITED STATES

Appellate Court Upholds Legality of
Hatch-Waxman Settlements between
Branded and Generic Drug Companies
On March 8, 2005, the Eleventh Circuit Court
of Appeals reversed a cease and desist order of
the FTC and upheld the legality of agreements
between a branded drug manufacturer and
two generic drug manufacturers settling patent
infringement litigation under the Hatch-Waxman
Act (Schering-Plough Corp. v. FTC). The FTC had
ruled that the settlements were a per se illegal
market allocation because they involved payments
by the branded company to the generics in
exchange for the generics’ agreement not to
market their products until certain dates. The
Eleventh Circuit disagreed and reversed the
order, holding that patents are presumed valid;
that the branded company had an absolute
right under its patent to exclude the generics
until patent expiration; and, therefore, that the
settlements—which provided for generic entry
earlier than the expiration of the patent—were
within the exclusionary scope of the patent. The
court also held that any anticompetitive effects
of the settlements were reasonably “ancillary” to
the “clear” pro-competitive efficiencies resulting
from the settlement of patent infringement suits.
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The decision has potential far-reaching
consequences, because a party aggrieved by
a decision of the FTC may appeal to any court
of appeals in which it does business. Thus, as a
practical matter, if the decision in Schering stands
(the FTC has filed a petition seeking an en banc
review, and if unsuccessful, could seek review by
the Supreme Court), it may become difficult, if
not impossible, for the FTC to challenge most
Hatch-Waxman settlements.
Schering-Plough v. FTC

EUROPE

Senior Executives Arrested on Suspicion
of Price Fixing

the Greek Competition Commission is not a
“court or tribunal,” it is unable to refer questions
for a preliminary ruling. The October 2004
Opinion of the Advocate-General therefore
provides the only guidance on this issue.
Syfait v. GlaxoSmithKline

STOP THE PRESS
Wilmer Cutler Pickering Hale and Dorr is
pleased to welcome Jeffrey K. Francer to
the firm. Jeffrey is an associate in the FDA
Department and will advise clients regarding
the regulation of drugs, biological products and
medical devices. Prior to joining the firm, Jeffrey
served as associate chief counsel of the FDA.

Two senior executives of Goldshield Group plc
were arrested on March 28, 2005, on suspicion
of fixing the price of generic drugs. The arrests
were made as part of an ongoing investigation
by the UK Serious Fraud Office (SFO) into
allegations that six drug companies fixed the
prices of generic versions of common antibiotics
(including the blood-thinning agent warfarin
and the ulcer drug Zantac) in the late 1990s.

We would like to give special thanks for this
edition to Corinne Atton, Hollie Baker, Jeffrey
Francer, Christopher Hutton, Peter Spaeth
and Colleen Superko.

One of the companies under investigtion,
Ranbaxy (UK) Ltd, reached a £4.5 million
settlement with the Department of Health
on April 1, 2005.

Contacts:

Following the introduction of the “cartel
offense” by the Enterprise Act of 2002,
it is an offense to dishonestly agree to fix
prices, limit or prevent supply or production,
share markets, or engage in bid-rigging.
The SFO’s investigation relates to alleged
price fixing that took place before the
introduction of the cartel offense. However,
the arrests highlight the increasing willingness
of the UK authorities to take action against
individuals engaged in cartel activity.

European Court of Justice Declines
Jurisdiction in Syfait v. GlaxoSmithKline
Following the report published in the Spring
2005 edition of PharmaBulletin, the ECJ stated, on
May 31, 2005, that it does not have jurisdiction
to rule on the issue referred by the Greek
Competition Commission—namely, whether
the protection of legitimate commercial interests
can justify a restriction of supply by a dominant
pharmaceutical company that is designed to
limit parallel trade. The ECJ held that, because
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